An Integrated Oncology Platform for Biomarker - CDx Development

Thursday October 15th, 15-15:30pm PDT
Dr Nicole Niu, Executive Director, Crown Bioscience

Greater preclinical knowledge is needed on patient responder subgroups, and the genetic background behind their response, to improve patient clinical stratification and reduce attrition rates. This knowledge helps to design smarter oncology trials and to speed up the development of next-generation cancer therapies and companion diagnostics.

Join our presentation to learn more about CrownBio's translational oncology expertise, share how pharmaceutical and diagnostic companies can partner in CDx development, and to explore the following case studies:

  • How MoA data from preclinical studies guided clinical development of RET-altered cancer therapy

  • How PDX mouse clinical trial and bioinformatics analysis offered evidence to support clinical observations from Phase III gastric cancer trials

  • The development and commercialization of a RAS and BRAF genetic mutation testing kit for accelerated market access and broad lab adoption of CDx for cetuximab and panitumumab in Japan

Visit the CrownBio Booth to Download Our Poster

An Automated Biomarker Discovery Platform based on In Vitro Pharmacology Raw Data

Learn more about the development of an automated biomarker discovery platform for in vitro preclinical pharmacology studies, combining an integrated suite of software facilities for data manipulation, calculation, and graphical display.


Arrange A Meeting at Biomarkers Series US

Your privacy is important to us.
We'll never share your information.